Loading provider…
Loading provider…
Medical Oncology Physician in San Francisco, CA
NPI: 1437113586Primary Practice Location
UCSF MEDICAL CENTER
1975 4th St, San Francisco, CA
Primary Employer
UCSF Medical Center
ucsfhealth.org
HQ Phone
Get MD Lawrence's Phone Numberphone_androidMobile
Get MD Lawrence's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1983 - 2025

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
Boston University Medical Center
Residency • Internal Medicine
1980 - 1983
UCSF School of Medicine
medschool.ucsf.edu
Fellowship • Hematology and Medical Oncology
1983 - 1985
David Geffen School of Medicine at UCLA
medschool.ucla.edu
Medical School
Until 1980
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 60 | 102 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 30 | 46 |
Hypoxia-specific imaging in patients with lymphoma undergoing CAR-T therapy.
Authors: Victoria Wang, Michael Spinner, Weiyun Ai, Bita Fakhri
Journal: Eur J Nucl Med Mol Imaging
Publication Date: 2023-06-10
Authors: Francisco Hernandez-Ilizaliturri, Ann Lacasce, John Byrd, David Doka, Bruce Cheson, John Leonard, Nancy Bartlett
Journal: Am J Hematol
Publication Date: 2020-04-06
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection
Authors: Paul Skolnik, Donald Northfelt, Paul Volberding, Margaret Fischl
Journal: Ann Intern Med
Lead Sponsor: University of California, San Francisco
Intervention / Treatment: DRUG: Busulfan
Lead Sponsor: University of California, San Francisco
Intervention / Treatment: DRUG: Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib
Lead Sponsor: AIDS Malignancy Consortium
Collaborators: National Cancer Institute (NCI), The Emmes Company, LLC
Intervention / Treatment: BIOLOGICAL: filgrastim, DRUG: doxorubicin hydrochloride, BIOLOGICAL: pegfilgrastim, BIOLOGICAL: rituximab, DRUG: ifosfamide, DRUG: methotrexate, DRUG: cyclophosphamide, DRUG: etoposide, DRUG: vincristine sulfate, DRUG: liposomal cytarabine, DRUG: therapeutic hydrocortisone, DRUG: leucovorin calcium, DRUG: cytarabine